Anil Dasu - AcelRx Pharmaceuticals Chief Officer
| ACRXDelisted Stock | USD 1.01 0.01 1.00% |
Insider
Anil Dasu is Chief Officer of AcelRx Pharmaceuticals
| Age | 61 |
| Phone | 650 216 3500 |
| Web | https://www.acelrx.com |
AcelRx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3222) % which means that it has lost $0.3222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5112) %, meaning that it created substantial loss on money invested by shareholders. AcelRx Pharmaceuticals' management efficiency ratios could be used to measure how well AcelRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.AcelRx Pharmaceuticals currently holds 10.42 M in liabilities with Debt to Equity (D/E) ratio of 0.43, which is about average as compared to similar companies. AcelRx Pharmaceuticals has a current ratio of 1.77, which is within standard range for the sector. Note, when we think about AcelRx Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Peisert | Assertio Therapeutics | 49 | |
| Mira Jung | Shuttle Pharmaceuticals | 76 | |
| Christopher Quesenberry | Evoke Pharma | N/A | |
| Denise Faltischek | Tilray Inc | 52 | |
| Jason Esq | Amneal Pharmaceuticals, Class | 51 | |
| Kenneth MD | Aquestive Therapeutics | N/A | |
| Tyvin MD | Shuttle Pharmaceuticals | 77 | |
| CSC MD | Shuttle Pharmaceuticals | 57 | |
| Alexander Schobel | Aquestive Therapeutics | 66 | |
| Albert Bolles | Lifecore Biomedical | 67 | |
| Bernard Yeung | Tilray Inc | N/A | |
| Jack Hoblitzell | Assertio Therapeutics | N/A | |
| Lloyd Brathwaite | Tilray Inc | N/A | |
| BA Esq | Organogenesis Holdings | 55 | |
| Brian Grow | Organogenesis Holdings | 49 | |
| Shlomo Yanai | Amneal Pharmaceuticals, Class | 68 | |
| Nikunj Patel | Amneal Pharmaceuticals, Class | N/A | |
| Michael Starkweather | Shuttle Pharmaceuticals | 40 | |
| Anthony DiMeo | Amneal Pharmaceuticals, Class | N/A | |
| BSBA Esq | Aquestive Therapeutics | 66 | |
| Jeffrey George | Amneal Pharmaceuticals, Class | 47 | |
Management Performance
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 |
AcelRx Pharmaceuticals Leadership Team
Elected by the shareholders, the AcelRx Pharmaceuticals' board of directors comprises two types of representatives: AcelRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AcelRx. The board's role is to monitor AcelRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. AcelRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AcelRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Angotti, CEO, Interim CFO | ||
| Anil Dasu, Chief Officer | ||
| Lawrence Hamel, Chief Devel. Officer | ||
| Pamela MD, Chief CoFounder | ||
| Raffi Asadorian, Chief Officer |
AcelRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AcelRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (28.28) % | |||
| Current Valuation | 3.25 M | |||
| Shares Outstanding | 16.95 M | |||
| Shares Owned By Insiders | 2.63 % | |||
| Shares Owned By Institutions | 38.88 % | |||
| Number Of Shares Shorted | 508.11 K | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 0.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |